Caroline Arber

Has grant

Research Group Leader, Attending Physician, Associate Professor

Lausanne University Hospital

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Caroline Arber is a Research Group Leader, Attending Physician, and Associate Professor at the University Hospital of Lausanne, Switzerland. Her research focuses on innovative strategies for managing CAR-T cell toxicity, as well as developments in antibody-peptide conjugates and cellular therapies for hematological malignancies. She has contributed to several recent articles exploring the implications of CAR-T treatments in Europe and advancing our understanding of T cell differentiation and macrophage signaling in cancer.

Recent Grants

Grant: Close

Chimeric antigen receptor T cell therapy for children and adults with relapsed acute myeloid leukemia (FIAMMA)

Open Date:

Close Date:

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

King’s College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Caroline Arber

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Novel strategies to manage CAR-T cell toxicity

Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT

Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997–2021

Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia

Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.

Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins.

Two to tango: engineered T cells against AML

Computational design of dynamic receptor—peptide signaling complexes applied to chemotaxis

Reductive carboxylation epigenetically instructs T cell differentiation

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization

Collaborators (7)

Michael Daskalakis

Holger Auner

Mathias Wenes

Patrick Barth

DENIS MIGLIORINI

Alexandre Benechet

Robert Jefferson

Make your next move.